Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s. This story matters for Technology readers tracking tech. Reported by techcrunch.com. Read the full original at the source link below.
Originally reported by techcrunch.com. TechNews curates and briefs the technology stories that matter. Our editorial policy →